Blood Test Detects Rheumatoid Arthritis 16 Years Before Onset

Article

Test diagnoses RA with better accuracy by detecting synthetic citrullinated peptides.

A reliable new blood test can test for rheumatoid arthritis (RA) years in advance. With about 1.5 million Americans suffering from the debilitating condition, according to the Centers for Disease Control and Prevention (CDC), early detection is key.

Researchers from the Kennedy Institute of Rheumatology at the University of Oxford in England discovered a biomarker that can predict the likelihood of developing RA. The blood test all starts by examining citrullination — the process where proteins are altered due to inflammation.

These changes can cause an immune response in the body where antibodies turn on themselves, which causes rheumatoid arthritis. Tests to detect these antibodies already exist, but with low sensitivity it is not the most reliable method. But a more general test called CCP can diagnose RA a lot more accurately by detecting synthetic citrullinated peptides.

“We knew that tenascin-C is found at high levels in the joints of people with RA. We decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA,” lead researcher Anja Schwenzer, PhD, said in a news release.

The team looked at blood test results from more than 2000 patients who had not been diagnosed with arthritis. They were able to diagnose RA in about half of the cases — some of which weren’t identified by standard testing – by targeting citrullinated tenascin-C (cTNC).

The method has a very low false positives rates and is 98% accurate at ruling out RA, according to the report in the Annals of the Rheumatic Diseases.

“What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred — on average the antibodies could be found seven years before the disease appeared,” explained Kim Midwood, BCs (Hons), PhD.

Early detection leads to more effective treatment, so not only does this additional test help increase the accuracy of the CCP assay, but it also helps spot RA way in advance which leads to better patient outcomes.

“This latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins,” concluded Stephen Simpson, PhD, research director at Arthritis Research UK.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.